Cyclooxygenase-2 expression and function in renal pathophysiology

Journal of Hypertension

Volumn 20, Issue SUPPL. 6, 2002, Pages

  Komers, Radko ^a   Epstein, Murray ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase 2; Diabetic nephropathy; Glomerulonephritis; Hypertension; Renal; Renin

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTANOID;

ANIMAL CELL; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SYNTHESIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY FUNCTION; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STIMULUS RESPONSE;

EID: 0036764484     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200212000-00001     Document Type: Conference Paper

References (46)

1. Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M. Interleukin-1-induced cyclooxygenase-2 expression is suppressed by cyclosporin in rat mesangial cells. Kidney Int 1995; 45:150-158.
2. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 1995; 95:1669-1675.
3. Tetsuka T, Daphna-Iken D, Miller BW, Guan Z, Baier LD, Morrison AR. Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells. J Clin Invest 1996; 97:2051-2056.
4. Hughes AK, Padilla E, Kutchera WA, Michael JR, Kohan DE. Endothelin-1 induction of cyclooxygenase-2 expression in rat mesangial cells. Kidney Int 1995; 47:53-61.
5. Goppelt-Struebe M, Weidemann T, Heusinger-Riberio J, Vucadinovic M, Rehm M, Prols F. COX-2 and osteopontin in cocultured platelets and mesangial cells: Role of glucocorticoids. Kidney Int 2000; 57:2229-2238.
6. Hirose S, Yamamoto T, Feng L, Yaoita E, Kawasaki K, Goto S, et al. Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 1998; 9:408-416.
7. Blume C, Heie G, Muhlfeld A, Bach D, Schror K, Gerhardz CD, et al. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999; 56:1770-1778.
8. 2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis. Inflamm Res 2000; 49:345-354.
9. Seibert K, Masferrer JL, Needleman P, Salvemini D. Pharmacological manipulation of cyclooxygenase-2 in the inflamed hydronephrotic kidney. Br J Pharmacol 1996; 117:1016-1020.
10. Tomasoni S, Noris M, Zappella S, Gotti E, Casiraghi F, Bonazzola S, et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998; 9:1202-1212.
11. Zoja C, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, et al. Mycophenolate mofetil (MMF) combined with a COX-2 inhibitor ameliorates murine lupus nephritis and prolongs animal life. J Am Soc Nephrol 2000; 11:A3339 (Abstract).
12. Schneider A, Harendza S, Zahner G, Jocks T, Wenzel U, Wolf G, et al. Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis. Kidney Int 1999; 55:430-441.
13. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 80:443-453.
14. Simons JL, Provoost AP, Anderson S, Rennke HG, Troy JL, Brenner BM. Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury. Kidney Int 1994; 46:396-404.
15. Ichihara A, Imig JD, Inscho EW, Navar LG. Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: Interaction with neuronal NOS. Am J Physiol 1998; 275:F605-F612.
16. Ichihara A, Imig JD, Navar LG. Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure. Hypertension 1999; 34:843-847.
17. Cheng HF, Wang JL, Zhang MZ, McKanna JA, Harris RC. Nitric oxide regulates renal cortical cyclooxygenase-2 expression. Am J Physiol 2000; 278:F122-F129.
18. Akai Y, Homma K, Burns K, Harris RC. Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase. Am J Physiol 1994; 267:C482-C490.
19. Wang JL, Cheng HF, Zhang MZ, McKanna JA, Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998; 275:F613-F622.
20. Sanchez PL, Salgado LM, Ferreri NR, Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 1999; 34:848-853.
21. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57:2334-2342.
22. Negrete H, Studer R, Craven P, DeRubertis F. Role for transforming growth factor beta in thromboxane-induced increases in mesangial cell fibronectine synthesis. Diabetes 1995; 44:335-339.
23. Weichert W, Paliege A, Provoost AP, Bachmann S. Upregulation of juxtaglomerular NOS1 and COX-2 precedes glomerulosclerois in fawn-hooded hypertensive rats. Am J Physiol 2001; 280:F706-F714.
24. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001; 107:889-898.
25. Wang JL, Cheng HF, Shappell S, Harris RC. Cyclooxygenase-2 (COX-2) inhibition decreases proteinuria in a hypertensive diabetic model. J Am Soc Nephrol 1999; 10:A3505 (Abstract).
26. Hartner A, Goppelt-Straube M, Hilgers KF. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 1998; 31:201-205.
27. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999; 34:96-101.
28. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999; 103:953-961.
29. Cheng HF, Wang JL, Zhang MZ, Wang SW, McKanna JA, Harris RC. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol 2001; 280:F449-F456.
30. Yang T, Endo Y, Huang Y, Smart A, Briggs JP, Schnermann JB. Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol 2000; 279:F819-F825.
31. Mann B, Hartner A, Jensen BL, Hilgers KF, Hocherl K, Kramer BK, et al. Acute upregulation of COX-2 by renal artery stenosis. Am J Physiol 2001; 280:F119-F125.
32. Castrop H, Schweda F, Schumacher K, Wolf K, Kurtz A. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol 2001; 12:867-874.
33. Mangat H, Peterson LN, Burns KD. Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. J Clin Invest 1997; 100:1941-1950.
34. Komers R, Tian W, Lindsley JN, Oyama TT, Cohen D, Anderson S. Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes. J Am Soc Nephrol 2001; 12:A2962 (Abstract).
35. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66:76-84.
36. Rodriguez F, Llinas MT, Gonzales JD, Rivera J, Salazar FJ. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 2000; 36:276-281.
37. Kömhoff M, Jeck NDM, Seyberth HW, Gröne H, Nüsing RM, Breyer D. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2001; 58:2420-2424.
38. Abassi Z, Brodsky S, Gealekman O, Rubinstein I, Hoffman A, Winaver J. Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am J Physiol 2001; 280:F43-F53.
39. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133:1-9.
40. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs non-steroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284:1247-1255.
41. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.
42. Whelton A, Fort JG, White WB, Goldstein J, Bello A, Verburg KM; SUCCESS VI Study Group. Cyclooxygenase-2 specific inhibitors and cardiorenal function: A randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8:85-95.
43. Daniels B, Gertz B, Morrison B. Renal safety profile of rofecoxib a specific inhibitor of COX-2 in controlled clinical trials. Arthritis Rheum 1999; 42:434.
44. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7:159-175.
45. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35:937-940.
46. Wolf G, Porth J, Stahl RA. Acute renal failure associated with rofecoxib. Ann Intern Med 2000; 133:394.